Title

Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials

Authors

Authors

M. Solh; R. I. Fisher; A. Goy; S. de Vos; S. H. Bernstein; D. L. Esseltine; R. Neuwirth;V. A. Morrison

Comments

Authors: contact us about adding a copy of your work at STARS@ucf.edu

Abbreviated Journal Title

Leuk. Lymphoma

Keywords

Herpes zoster; bortezomib; non-Hodgkin lymphoma; mantle cell lymphoma; MULTIPLE-MYELOMA; PLUS MELPHALAN; DEXAMETHASONE; PREDNISONE; ACYCLOVIR; Oncology; Hematology

Abstract

The incidence of herpes zoster (HZ) in patients with non-Hodgkin lymphoma (NHL) receiving bortezomib-based therapy has not been well studied. We reviewed data from two phase II trials in which bortezomib was administered to 236 patients, median age 65 years, with relapsed/refractory mantle cell or indolent NHL. HZ occurred in 24 patients (10.2%) overall, with a comparable incidence in NHL histologic subgroups. Median time to HZ was 39 (range, 11-206) days. In total, 71% of patients who developed HZ were aged >= 65 years, compared to 48% without HZ (p = 0.03). Patients with HZ were more likely to have had received >= 2 lines of therapy (63% vs. 47%, p = 0.16). Six (25%) of the patients who developed HZ had received purine analogs, compared with 34 (16%) patients without HZ (p = 0.27). As the occurrence of HZ may complicate the course of indolent or mantle cell NHL in patients receiving bortezomib-based therapies, these patients, especially the elderly, should be strongly considered for antiviral prophylaxis.

Journal Title

Leukemia & Lymphoma

Volume

54

Issue/Number

10

Publication Date

1-1-2013

Document Type

Article

Language

English

First Page

2185

Last Page

2189

WOS Identifier

WOS:000324589800019

ISSN

1042-8194

Share

COinS